Kamat Sandhya K, Barde Prajakt J, Raut Sanket B
Department of Pharmacology and Therapeutics, King Edward Memorial Hospital and Seth Gordhandas Sunderdas Medical College, Mumbai, Maharashtra, India.
Department of Clinical Research, Rhizen Pharmaceutical SA, Switzerland.
Anc Sci Life. 2015 Oct-Dec;35(2):90-5. doi: 10.4103/0257-7941.171669.
The objective of the study was to evaluate the estrogenic activity of four Indian medicinal plants Saraca indica (Si), Symplocos racemosa (Sr), Cyperus rotundus (Cr), Terminalia arjuna (Ta), a marketed preparation of Si (Aśokāriṣṭa) and a combination of Si + Sr using an experimental model of estrogenicity.
After approval of the institutional animal ethics committee, 22 day old female rats (n = 54) were randomly allocated to 9 groups - Group 1 and Group 2: Vehicle controls, Group 3: Ethinyl estradiol, Group 4: Si (270 mg/kg), Group 5: Sr (270 mg/kg), Group 6: Cr (540 mg/kg), Group 7: Ta (270 mg/kg), Group 8: Ashokarishta (4 ml/kg), Group 9: Si + Sr (135 mg/kg). Variables studied were: Body weight, uterine weight, relative uterine weight, presence of vaginal opening, histomorphology of the uterus and total uterine glycogen content. Parametric data were analyzed using one-way ANOVA and the categorical data were analyzed using Chi-square test.
All animals in the ethinyl estradiol group showed a significant change in all the variables. None of the individual test drugs, neither the marketed preparation produced change in any of the variables. The plant drug combination also did not produce a change in any of the variables studied except in histomorphology wherein it caused a slight increase in the height of the luminal epithelium of the uterus (P < 0.05 vs. Group 1).
The plant drugs Si, Sr, Cr, Ta and Aśokāriṣṭa did not demonstrate estrogenic activity in the immature rat model. The plant drug combination Si + Sr showed questionable estrogenic activity which needs to be evaluated in further studies.
本研究的目的是使用雌激素活性实验模型评估四种印度药用植物——无忧花(Si)、总序山矾(Sr)、香附子(Cr)、印度楝(Ta)、一种市售的无忧花制剂(阿输迦利什塔)以及Si + Sr组合的雌激素活性。
经机构动物伦理委员会批准后,将22日龄的雌性大鼠(n = 54)随机分为9组——第1组和第2组:溶剂对照组,第3组:炔雌醇,第4组:Si(270毫克/千克),第5组:Sr(270毫克/千克),第6组:Cr(540毫克/千克),第7组:Ta(270毫克/千克),第8组:阿输迦利什塔(4毫升/千克),第9组:Si + Sr(135毫克/千克)。所研究的变量包括:体重、子宫重量、相对子宫重量、阴道开口情况、子宫组织形态学以及子宫总糖原含量。参数数据采用单因素方差分析进行分析,分类数据采用卡方检验进行分析。
炔雌醇组的所有动物在所有变量上均表现出显著变化。任何一种单独的受试药物以及市售制剂均未使任何变量发生变化。植物药组合除了在组织形态学方面使子宫腔上皮高度略有增加(与第1组相比,P < 0.05)外,在所研究的任何变量上也未产生变化。
植物药Si、Sr、Cr、Ta以及阿输迦利什塔在未成熟大鼠模型中未表现出雌激素活性。植物药组合Si + Sr显示出可疑的雌激素活性,需要在进一步研究中进行评估。